This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Health Stock Winners and Losers: Bristol, Glaxo

Updated from 12:42 p.m. EDT

Health care stocks were faring well Tuesday, this 12th day of May, despite a undulating broader market.

Bristol-Myers Squibb (BMY - Get Report) announced Tuesday that it would confirm its earnings forecast at the Bank of America and Merrill Lynch Health Care Conference on Wednesday in New York. Last month the company said it expects full-year earnings in the range of $1.58 to $1.73 a share. Bristol shares were tacking on 1% to $20.50 in recent trading.

GlaxoSmithKline (GSK - Get Report) announced that it was acquiring a 16% stake in South Africa-based Aspen Pharmacare in exchange for a divestiture of assets including eight specialist medicines and a manufacturing facility in Bad Oldesloe, Germany.

Glaxo said the impact of this transaction to earnings per share is expected to be accretive in 2009 and slightly dilutive in 2010. Glaxo shares were recently up 2.9% to $31.83.

Pfizer (PFE - Get Report) shares were rising after analysts Credit Suisse called the stock undervalued given the company's impending merger with Wyeth (WYE). The analysts also said the company could raise its dividend soon, according to The Associated Press.

Also on Tuesday, Pfizer announced that Greg Simon, former president of FasterCures, is its new senior vice president for worldwide policy. Simon, who holds a law degree and was a chief domestic policy advisor for Vice President Al Gore, will be responsible for counsel and action on health care, science and technology policy issues. Pfizer shares were recently up 5.2% to $14.88.

Novo Nordisk (NVO - Get Report) shares were up 2.7% to $50.18. Piper Jaffray initiated coverage on the stock with a "buy" rating.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
BMY $71.24 0.13%
GSK $42.13 -0.68%
LLY $74.58 -0.92%
NVO $53.35 -0.35%
MRK $53.60 -0.91%


Chart of I:DJI
DOW 17,740.63 +79.92 0.45%
S&P 500 2,057.14 +6.51 0.32%
NASDAQ 4,736.1550 +19.0610 0.40%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs